Objective: To evaluate the safety and efficacy of human stem cells for bronchopulmonary dysplasia in preterm infants. Study design: From inception to September 2020, the PubMed, Web of Science, Cochrane Library and CNKI databases as well as ClinicalTrials.gov were searched for relevant reports. All the clinical trials, case reports, case series and letters were included. The included results were analyzed by Stata 16.0. Results: There were no statistically significant differences between the trial and control groups with respect to the number of deaths (OR [95% CI]: 0.619 [0.089, 4.316]) or bronchopulmonary dysplasia cases (OR [95% CI]: 1.138[0.040, 32.36]). The incidences of serious adverse events and dose-limiting toxicities were not significantly different between the two groups. There was a significant statistical difference between the trial and control groups in the mechanical ventilation duration (P<0.05) and duration of oxygen (P<0.05). Conclusion: The infusion of human cord blood stem cells into premature infants does not increase the risk of serious adverse events or death, and this therapy may decrease the mechanical ventilation duration and duration of oxygen administration.